What is the Ironwood Pharmaceuticals Inc. stock price forecast?

Ironwood Pharmaceuticals Inc. is currently trading at $3.66. View real-time AI analysis on Alpha Lenz.

What is Ironwood Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Ironwood Pharmaceuticals Inc. on Alpha Lenz.

What is Ironwood Pharmaceuticals Inc.'s P/E ratio?

Ironwood Pharmaceuticals Inc.'s P/E ratio is 24.7.

Ironwood Pharmaceuticals Inc.

NASDAQ · IRWD

$3.66-0.03(-0.81%)Pre-market

Ask about Ironwood Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“Ironwood Pharmaceuticals Inc. trades at a P/E of 24.7 (fair value) with modest ROE of -8.5%. Operating margin of 40.1% indicates strong profitability.”

Ask for details →

Company Overview

Ironwood Pharmaceuticals Inc. is a healthcare and pharmaceuticals company specializing in the development and commercialization of drugs for gastrointestinal conditions. Headquartered in Cambridge, Massachusetts, Ironwood focuses on designing novel treatments that address unmet medical needs, particularly for conditions like irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company's flagship product is linaclotide, marketed under the brand name Linzess, which is a leading therapeutic option for IBS-C and CIC patients across the United States and several international markets. Ironwood Pharmaceuticals also engages in partnerships to enhance drug development and expand its market reach. Through a commitment to innovative research and strategic collaborations, Ironwood plays a significant role in the biotechnology sector, aiming to improve patient outcomes and health care experiences worldwide.

CEOMr. Thomas A. McCourt

Websitehttps://ironwoodpharma.com

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees253

Company Statistics

FY 2025

Profile

$592.34MMarket Cap

$296.15MRevenue

0.00Shares Out

253Employees

Margins

N/AGross

42.18%EBITDA

40.10%Operating

23.65%Pre-Tax

8.11%Net

Valuation

24.66P/E

-2.26P/B

2.00EV/Sales

7.80EV/EBITDA

4.66P/FCF

Growth (CAGR)

-10.32%Rev 3Yr

-5.33%Rev 5Yr

-22.01%Op Inc 3Yr

-5.59%Op Inc 5Yr

-48.42%Net Inc 3Yr

-25.72%Net Inc 5Yr

Returns

6.42%ROA

-8.53%ROE

27.49%ROIC

Financial Health

$215.46MCash & Cash Equivalents

$443.28MNet Debt

-251.58%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Ironwood Pharmaceuticals Inc. trades at a P/E of 24.7 (fair value) with modest ROE of -8.5%. Operating margin of 40.1% indicates strong profitability.”

Ask for details →

Frequently Asked Questions

Ironwood Pharmaceuticals Inc. (ticker: IRWD) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 253 employees. Market cap is $592M.

The current price is $3.66 with a P/E ratio of 24.66x and P/B of -2.26x.

ROE is -8.53% and operating margin is 40.10%. Annual revenue is $296M.